Bristol-Myers (BMY) +5.1% after disclosing late yesterday that a Phase III study of its...

|About: Bristol-Myers Squibb Com... (BMY)|By:, SA News Editor

Bristol-Myers (BMY) +5.1% after disclosing late yesterday that a Phase III study of its ipilimumab melanoma drug achieved its primary endpoint of improving overall survival. Going forward, BMY is also likely to test efficacy of ipilimumab in prostate cancer and lung cancer.